The DCR of patients treated with Osimertinib was 92.5% (738/798), whereas the DCR of those treated with EGFR-TKIs/chemotherapy was 80.1% (507/633), which indicated that the Osimertinib therapy subgroup could obtain higher a DCR than the EGFR-TKIs/chemotherapy subgroup in advanced NSCLC patients with EGFR mutations, regardless of the full analysis set or subgroup set (full analysis: OR = 1.18, 95% CI = 1.02–1.37, P = .028; T790M mutation subgroup: OR = 1.38, 95% CI = 1.04–1.84, P = .028; Ex19del and/or L858R mutation subgroup: OR = 1.05, 95% CI = 1.02–1.10, P = .006) (Fig. 4B). Here, EGFR is linked to non-small cell lung carcinoma.